A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison DOI Creative Commons
Roberta Antonelli,

Vittoria Forconi,

Eleonora Molesti

и другие.

F1000Research, Год журнала: 2024, Номер 13, С. 534 - 534

Опубликована: Окт. 14, 2024

Over the past few decades, World Health Organization (WHO) has made massive efforts to promote development of a vaccine against Lassa virus (LASV), one top ten priority pathogens for research and under WHO R&D Blueprint Emerging Infections. To date, several vaccines are at different stages development. In this scenario, validated standardised assay measure LASV neutralising antibodies is urgently needed comparison.

Язык: Английский

Clonal Interference and Changing Selective Pressures Shape the Escape of Sars-Cov-2 from Hundreds of Antibodies DOI
Hugh K. Haddox,

O. Aziz,

Jared Galloway

и другие.

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

Deep mutational scanning and CRISPR-engineered viruses: tools for evolutionary and functional genomics studies DOI Creative Commons
Mercedes Paz, Gonzalo Moratorio

mSphere, Год журнала: 2025, Номер unknown

Опубликована: Апрель 24, 2025

ABSTRACT Recent advancements in synthetic biology and sequencing technologies have revolutionized the ability to manipulate viral genomes with unparalleled precision. This review focuses on two powerful methodologies: deep mutational scanning CRISPR-based genome editing, that enable comprehensive mutagenesis detailed functional characterization of proteins. These approaches significantly deepened our understanding molecular determinants driving evolution adaptation. Furthermore, we discuss how these advances provide transformative insights for future vaccine development therapeutic strategies.

Язык: Английский

Процитировано

0

Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV DOI Creative Commons

Shaoyan Wang,

Ruihua Li, Xiaoyan Pan

и другие.

npj Vaccines, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 22, 2025

Lassa virus (LASV) belongs to the Arenaviridae family and causes severe hemorrhagic fever in humans. Although many vaccine candidates for exist, no vaccines have been approved clinical use currently. The precursor glycoprotein complex (GPC), which is expressed as a trimer on viral surface, main target development. However, it has significant challenge elicit effective neutralizing antibodies against LASV. In this study, we designed produced prefusion GPC antigen of LASV, named GPCv2. Based structural information GPC, made modifications by replacing amino acid at position 328 with proline appending trimerization domain. This resulted highly trimeric form GPCv2 that retained important conformational epitopes stimulated higher levels antibodies. Moreover, vaccination protected mice from LASV pseudovirus challenge. Additionally, immune repertoire sequencing showed induced clones group were more convergent its own unique V-J pairing bias compared monomeric group. These findings demonstrate potential promising candidate an

Язык: Английский

Процитировано

0

Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations DOI Creative Commons
Arjun K. Aditham,

Caelan E. Radford,

Caleb R. Carr

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Дек. 17, 2024

Abstract Rabies virus causes nearly 60,000 human deaths annually. Antibodies that target the rabies glycoprotein (G) are being developed as post-exposure prophylactics, but mutations in G can render such antibodies ineffective. Here, we use pseudovirus deep mutational scanning to measure how all single amino-acid affect cell entry and neutralization by a panel of antibodies. These measurements identify sites critical for G’s function, define constrained regions attractive epitopes clinical antibodies, including at apex base protein. We provide complete maps escape eight monoclonal some or development. Escape most present natural strains. Overall, this work provides comprehensive information on functional antigenic effects help inform development stabilized vaccine antigens resilient genetic variation.

Язык: Английский

Процитировано

1

Machine Learning Reveals Key Glycoprotein Mutations and Rapidly Assigns Lassa Virus Lineages DOI Creative Commons
Richard Olumide Daodu, Jens-Uwe Ulrich, Denise Kühnert

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Июль 31, 2024

Abstract Lassa fever, caused by the virus (LASV), remains a major public health concern in West Africa, causing numerous fatalities annually and several intercontinental cases since its discovery 1969. Despite ongoing research, no approved vaccines are available, with current efforts focusing on immunotherapy. LASV is divided into distinct lineages that circulate specific geographic regions, elicit varying immune responses, exhibit different pathophysiological effects. Understanding genetic differences between these crucial for developing, improving, distributing diagnostics, treatments, vaccines. In this study, we analyzed glycoprotein complex (GPC), only surface protein, using statistics, machine learning, phylogenetics. At population scale, identified key amino acid Nigerian those other African particularly near stable signal peptide cleavage site immune-related regions (e.g., AA positions 59–76). Additionally, found GPC sequences from Lineages II III shorter than Lineage IV, due to high prevalence of codon insertion at 178–180 (amino position 60). This may contribute inaccuracies observed molecular diagnostics also play role increased fatality associated IV. The has reemerged persisted which indicate fitness advantage. Furthermore, developed fast highly accurate lineage classification tool called CLASV allows rapid identification lineages, improving ability monitor emerging outbreaks exported cases.

Язык: Английский

Процитировано

0

A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison DOI Creative Commons
Roberta Antonelli,

Vittoria Forconi,

Eleonora Molesti

и другие.

F1000Research, Год журнала: 2024, Номер 13, С. 534 - 534

Опубликована: Окт. 14, 2024

Over the past few decades, World Health Organization (WHO) has made massive efforts to promote development of a vaccine against Lassa virus (LASV), one top ten priority pathogens for research and under WHO R&D Blueprint Emerging Infections. To date, several vaccines are at different stages development. In this scenario, validated standardised assay measure LASV neutralising antibodies is urgently needed comparison.

Язык: Английский

Процитировано

0